-
Cotation en bourse
-
Trading
Where European Government Bonds meet the futureFixed Income derivativesLire la suiteTrade Mini Bond Futures on main European Government Bonds
-
Clearing
Step into Europe’s next phase of Repo ClearingRepo ClearingLire la suiteEuronext is expanding its repo clearing services to boost market access, liquidity provision and collateral optimisation across Europe.
-
CSD
European CSD modelBuilding the CSD of Choice in EuropeLire la suiteEuronext Securities is shaping the future of European capital markets by enhancing integration, connectivity, and innovation.
-
Technology
Euronext Technology SolutionsHigh-Frequency Trading Solution (HFTS)Lire la suiteThe new generation of high-frequency risk trading platforms, offering the highest performance with ultra-low latency and minimal jitter, all at a low total cost of ownership.
-
Data
-
Indices
Access the white paperInvesting in the future of Europe with innovative indicesLire la suiteThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
-
About Euronext
Euronext strategic planInnovate for Growth 2027Lire la suiteShaping capital markets for future generations
NFL Biosciences s'introduit sur Euronext Growth Paris
05/07/2021
Ignacio Faus, Directeur Général, et Bruno Lafont, co-Fondateur et Directeur Général Délégué de NFL Biosciences, ouvrent les marchés financiers à Paris.
NFL Biosciences est spécialisé dans la recherche et le développement de médicaments destinés à lutter contre l’addiction au tabac avec des agents botaniques et pharmaceutiques.
La société dispose d’un produit en phase de développement clinique (NFL-101).